Zacks Research Has Positive Forecast for CRL Q2 Earnings

Charles River Laboratories International, Inc. (NYSE:CRL) – Equities researchers at Zacks Research increased their Q2 2026 earnings per share (EPS) estimates for shares of Charles River Laboratories International in a note issued to investors on Monday, April 7th. Zacks Research analyst R. Department now anticipates that the medical research company will earn $2.67 per share for the quarter, up from their previous estimate of $2.66. The consensus estimate for Charles River Laboratories International’s current full-year earnings is $9.36 per share.

Charles River Laboratories International (NYSE:CRL) last posted its quarterly earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.50 by $0.16. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The business had revenue of $1 billion for the quarter, compared to analysts’ expectations of $983.63 million. During the same quarter last year, the business earned $2.46 earnings per share. The firm’s quarterly revenue was down 1.1% compared to the same quarter last year.

Other equities analysts have also recently issued research reports about the company. Citigroup upgraded Charles River Laboratories International from a “sell” rating to a “neutral” rating and raised their price objective for the company from $155.00 to $175.00 in a report on Tuesday, March 4th. UBS Group restated a “neutral” rating and set a $185.00 target price (down previously from $250.00) on shares of Charles River Laboratories International in a research note on Friday, January 17th. Robert W. Baird decreased their price objective on Charles River Laboratories International from $177.00 to $173.00 and set a “neutral” rating on the stock in a report on Thursday, February 20th. William Blair cut Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a research note on Wednesday, January 22nd. Finally, JPMorgan Chase & Co. reduced their price target on shares of Charles River Laboratories International from $175.00 to $165.00 and set a “neutral” rating on the stock in a research report on Thursday, February 20th. One investment analyst has rated the stock with a sell rating and sixteen have assigned a hold rating to the stock. According to MarketBeat.com, Charles River Laboratories International has a consensus rating of “Hold” and an average price target of $183.62.

Charles River Laboratories International Stock Up 12.4 %

Charles River Laboratories International stock opened at $138.91 on Wednesday. The stock has a market capitalization of $6.82 billion, a PE ratio of 926.07, a price-to-earnings-growth ratio of 4.54 and a beta of 1.45. The company has a quick ratio of 1.14, a current ratio of 1.41 and a debt-to-equity ratio of 0.65. Charles River Laboratories International has a twelve month low of $117.26 and a twelve month high of $254.15. The company has a 50 day moving average of $159.23 and a 200-day moving average of $178.36.

Insider Buying and Selling at Charles River Laboratories International

In other news, COO Birgit Girshick acquired 1,514 shares of the firm’s stock in a transaction on Thursday, February 20th. The stock was acquired at an average price of $164.63 per share, for a total transaction of $249,249.82. Following the completion of the acquisition, the chief operating officer now owns 55,058 shares in the company, valued at $9,064,198.54. This trade represents a 2.83 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO James C. Foster purchased 6,075 shares of the company’s stock in a transaction dated Thursday, February 20th. The stock was bought at an average cost of $165.01 per share, for a total transaction of $1,002,435.75. Following the completion of the transaction, the chief executive officer now owns 183,639 shares in the company, valued at approximately $30,302,271.39. This represents a 3.42 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.30% of the stock is currently owned by corporate insiders.

Institutional Trading of Charles River Laboratories International

Several institutional investors and hedge funds have recently modified their holdings of CRL. Benjamin Edwards Inc. raised its position in shares of Charles River Laboratories International by 256.5% during the third quarter. Benjamin Edwards Inc. now owns 1,451 shares of the medical research company’s stock valued at $286,000 after buying an additional 1,044 shares during the last quarter. State Street Corp increased its holdings in Charles River Laboratories International by 2.0% in the 3rd quarter. State Street Corp now owns 2,130,279 shares of the medical research company’s stock valued at $419,601,000 after acquiring an additional 41,421 shares during the last quarter. EP Wealth Advisors LLC purchased a new stake in Charles River Laboratories International in the 3rd quarter worth $273,000. National Bank of Canada FI grew its position in shares of Charles River Laboratories International by 45.4% during the third quarter. National Bank of Canada FI now owns 21,216 shares of the medical research company’s stock valued at $4,179,000 after purchasing an additional 6,627 shares in the last quarter. Finally, Nomura Asset Management Co. Ltd. increased its holdings in shares of Charles River Laboratories International by 13.7% in the third quarter. Nomura Asset Management Co. Ltd. now owns 15,592 shares of the medical research company’s stock worth $3,071,000 after purchasing an additional 1,882 shares during the last quarter. 98.91% of the stock is currently owned by institutional investors.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).